{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Will be calculated overall and by treatment arm.","groups":[{"description":"Induction therapy + single myeloablative consolidation","id":"OG000","title":"Single HST (CEM)"},{"description":"Induction therapy + tandem myeloablative consolidation","id":"OG001","title":"Tandem HST (CEM), Randomly Assigned"},{"description":"All Eligible Patients","id":"OG002","title":"All Eligible Patients"}],"populationDescription":"Data were not collected to assess this study aim.","reportingStatus":"POSTED","timeFrame":"Baseline","title":"Proportion of Patients With Neuroblastoma Detected in Bone Marrow and Peripheral Blood Using RT-PCR Technique","type":"SECONDARY"}